EBV-miR-BART-22 can promote the metastasis, invasion, and EMT of NPC cells by targeting MOSPD2 to activate the Wnt/β-catenin signaling pathway (Fig. 8). This evidence concerns the gene MOSPD2 and nasopharyngeal carcinoma.